Replies to post #119042 on Biotech Values

[mcbio]

In today's 8-K AVEO pushed back the expected date for TIVO-1 phase III topline data from mid-2011 to Q4. Since this is an event based trial, the extended timeline could bode well for the outcome.

How do you know it's not the control arm, or both arms, that are responsible for the extended timeline?